FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?
Lilly/Daiichi’s platelet inhibitor prasugrel will be subject of Feb. 3 advisory committee; outcome could hinge on makeup of expert panel.
Lilly/Daiichi’s platelet inhibitor prasugrel will be subject of Feb. 3 advisory committee; outcome could hinge on makeup of expert panel.